Invention for Production at commercial scale of nanoparticles encapsulated

Invented by Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch, Iceutica Pty Ltd

in polymers

Nanoparticles encapsulated in polymers have become increasingly popular in recent years due to their unique properties and potential applications in various industries. These nanoparticles are typically less than 100 nanometers in size and are encapsulated in a polymer matrix, which provides stability, protection, and controlled release properties.

The market for production at commercial scale of nanoparticles encapsulated in polymers is expected to grow significantly in the coming years. This growth is driven by the increasing demand for advanced materials with unique properties, such as improved drug delivery systems, enhanced imaging agents, and more efficient catalysts.

One of the major advantages of nanoparticles encapsulated in polymers is their ability to improve the bioavailability and efficacy of drugs. By encapsulating drugs in nanoparticles, they can be targeted to specific cells or tissues, resulting in more effective treatment with fewer side effects. This has led to a growing interest in the development of nanoparticle-based drug delivery systems, which is expected to drive the growth of the market.

Another area where nanoparticles encapsulated in polymers are expected to have a significant impact is in the field of imaging. These nanoparticles can be engineered to have specific optical and magnetic properties, making them ideal for use as contrast agents in medical imaging. This has led to the development of new imaging techniques, such as magnetic resonance imaging (MRI) and optical imaging, which are expected to drive the growth of the market.

In addition to their applications in drug delivery and imaging, nanoparticles encapsulated in polymers are also being explored for use as catalysts. These nanoparticles can be engineered to have specific catalytic properties, making them ideal for use in a wide range of industrial applications, such as the production of chemicals and fuels. This has led to a growing interest in the development of nanoparticle-based catalysts, which is expected to drive the growth of the market.

Overall, the market for production at commercial scale of nanoparticles encapsulated in polymers is expected to grow significantly in the coming years. This growth is driven by the increasing demand for advanced materials with unique properties, such as improved drug delivery systems, enhanced imaging agents, and more efficient catalysts. As research and development in this field continues, we can expect to see even more innovative applications of these nanoparticles in the future.

The Iceutica Pty Ltd invention works as follows

The present invention is directed to dry milling methods and compositions containing biologically-active materials. It also relates to medicaments made from said materials in particle form or compositions. And it relates to treatment methods using therapeutically-effective amounts of these materials.

Background for Production at commercial scale of nanoparticles encapsulated

General

Particle Size

Other Definitions

Specific

Commercial Scale

Improve the Dissolution Profile

Crystallization Profile

Amorphicity Profile

Grinding Matrix

Milling Bodies

Dry Milling

Biologically active material

Processed biologically active material

Processing Time

Biologically active materials and compositions

Medicaments

Modes of Administration of Medicaments Containing Biologically Active Material

EXAMPLES

Spex-Type Mill:

Attritor-Type Mill:

Siebtechnik Mill

Click here to view the patent on Google Patents.


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *